Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zevra Therapeutics (ZVRA) EPS (Weighted Average and Diluted) (2016 - 2025)

Zevra Therapeutics (ZVRA) has disclosed EPS (Weighted Average and Diluted) for 7 consecutive years, with $0.19 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Weighted Average and Diluted) rose 127.54% year-over-year to $0.19, compared with a TTM value of -$0.01 through Dec 2025, up 98.41%, and an annual FY2025 reading of $1.35, up 159.21% over the prior year.
  • EPS (Weighted Average and Diluted) was $0.19 for Q4 2025 at Zevra Therapeutics, up from -$0.01 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $1.21 in Q2 2025 and bottomed at -$2.49 in Q1 2021.
  • Average EPS (Weighted Average and Diluted) over 3 years is -$0.26, with a median of -$0.2 recorded in 2025.
  • The sharpest move saw EPS (Weighted Average and Diluted) crashed 4100.0% in 2021, then skyrocketed 354.44% in 2025.
  • Year by year, EPS (Weighted Average and Diluted) stood at $0.05 in 2021, then tumbled by 1480.0% to -$0.69 in 2024, then surged by 127.54% to $0.19 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for ZVRA at $0.19 in Q4 2025, -$0.01 in Q3 2025, and $1.21 in Q2 2025.